Table 1.
4/2 Schedule (n=8) | 2/1 Schedule (n=8) | |||||||
---|---|---|---|---|---|---|---|---|
Treatment | Withdrawal | Treatment | Withdrawal | |||||
Median Change (Range) | p-value | Median Change (Range) | p-value | Median Change (Range) | p-value | Median Change (Range) | p-value | |
Sunitinib, Css (ng/mL) | 63 (37 – 184) | 0.005 | −59 (−181 – −32) | 0.008 | 62 (−32 – 162) | 0.008 | −51 (−104 – −23) | 0.008 |
Sunitinib met, Css (ng/mL) | 20 (14 – 39) | <0.001 | −18 (−29 – −5) | 0.008 | 21 (5 – 52) | 0.008 | −16 (−26 – −1) | 0.008 |
VEGF (pg/mL) | 168 (51 – 461) | 0.008 | −184 (−448 – −22) | 0.008 | 100 (18 – 361) | 0.008 | −96 (−253 – −26) | 0.008 |
SUVmean (% change) | −16 (−100 – 0) | 0.031 | 15 (−14 – 277) | 0.047 | −18 (−64 – 6) | 0.109 | 19 (−5 – 200) | 0.047 |
SUVmax (% change) | −34 (−100 – 4) | 0.016 | 33 (−18 – 221) | 0.078 | −21 (−64 – 6) | 0.039 | 28 (−33 – 251) | 0.109 |